The cardiac safety assessment assays are available for preclinical evaluation of the safety of compounds to identify toxic drugs potentially inducing fatal cardiac tachyarrhythmia.
Ion channels are a diverse class of membrane proteins that play important roles in physiology. Deficits or the increase of ion channel activity caused by the activity of pharmacological agents are linked to several disease conditions. The inhibition of cardiac ion channels is linked to the generation of life-threatening arrhythmias. Therefore it is important to screen compounds against these channels to assess potential cardiac liability.
Testingthecorepanelis a reasonablefirststepforassessmentofcardiacsafetyof a newdrug. Testingwhether a drugblocksionchannels hERG, Cav1.2 and Nav1.5 will helpwithgo/no-godecisionsearly in thedrugdiscoveryprocess.
Via our collaborator PharmaCore Labs (PCL) Co., Ltd we offer ion channel cardiac assessment according to CiPA (Comprehensive in vitro Proarrhythmia Assay) guidelines for standardized procedures necessary for regulatory decision-making to advance drug development programs.
Testing of drug-induced action potential prolongation and changes in the QT interval help evaluate the side effects of new drug candidates to ensure cardiac safety.